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Very long chain fatty acids (VLCFA)X-linked adrenoleukodystrophy (X-ALD) is a severe neurodegenerative disorder resulting from defective ABCD1
transport protein. ABCD1 mediates peroxisomal uptake of free very-long-chain fatty acids (VLCFA) as well as
their CoA-esters. Consequently, VLCFA accumulate in patients' plasma and tissues, which is considered as path-
ogenic X-ALD triggering factor. Clinical symptoms are mostly manifested in neural tissues and adrenal gland.
Here, we investigate astrocytes fromwild-type control and a genetic X-ALDmousemodel (Abcd1-knockout), ex-
posed to supraphysiological VLCFA (C22:0, C24:0 and C26:0) concentrations. They exhibit multiple impairments
of energymetabolism. Furthermore, brainmitochondria from Abcd1−/−mice andwild-type control respond sim-
ilarly to VLCFAwith increased ROS generation, impaired oxidative ATP synthesis and diminished Ca2+ uptake ca-
pacity, suggesting that a defective ABCD1 exerts no adaptive pressure on mitochondria. In contrast, astrocytes
from Abcd1−/− mice respond more sensitively to VLCFA than wild-type control astrocytes. Moreover, long-
term application of VLCFA induces high ROS generation, and strong in situ depolarization of mitochondria, and,
in Abcd1−/− astrocytes, severely diminishes the capability to revert oxidized pyridine nucleotides to NAD(P)H.
In addition, observed differences in responses of mitochondria and astrocytes to the hydrocarbon chain length
of VLCFA suggest that detrimental VLCFA activities in astrocytes involve defective cellular functions other than
mitochondria. In summary, we clearly demonstrate that VLCFA increase the vulnerability of Abcd1−/− astrocytes.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
With a minimal incidence of 1:20,000 births, X-linked adrenoleuko-
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g, Germany. Tel.: +49 391 67peroxisomal disorders. Striking biochemical feature of X-ALD is the en-
richment of very long chain fatty acids (VLCFA), such as C24:0, C26:0,
and possibly also C26:1, in plasma and tissue of patients suffering
from X-ALD [1,2]. Characteristic for X-ALD is mutations in the Abcd1
gene, encoding for the peroxisomal ATP-binding cassette (ABC)-trans-
porter adrenoleukodystrophy protein (ALDP/ABCD1) [3]. Defective
Abcd1 gene decreases the uptake of VLCFA as well as the CoA-esters of
VLCFA into peroxisomes and thus, impairs the degradation of VLCFA
by the peroxisomal β-oxidation pathway [4,5].
Elevated VLCFA levels appear to be correlated to the clinical outcome,
which is characterized in themost severe cases by lethal progressive and
multifocal demyelination, adrenal insufﬁciency, and inﬂammation [6].
The clinical phenotypic expression of X-ALD has a very broad variability,
ranging from the fatal childhood cerebral form (cALD) to themore slow-
ly progressing adult form, the adrenomyeloneuropathy (AMN) [7]. No
correlation between mutations in the ABCD1 gene and clinical pheno-
types could be observed in several studies, suggesting that further genet-
ic or environmental factors might contribute to the disease state [8–11].
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developed independently in three laboratories [12–14] displays bio-
chemical abnormalities, like reduced VLCFA β-oxidation and accumula-
tion of VLCFA, similar to the situation seen in patients. However, Abcd1-
knockout mice develop a late onset neurological phenotype that
resembles the AMN phenotype and not cALD [15].
Like in other peroxisomal diseases, the molecular mechanism of the
X-ALD pathogenesis is still elusive. There are two different research par-
adigms to uncover the X-ALD pathogenesis. Impairment of axonal func-
tion by demyelination is a hallmark of several neurodegenerative
diseases caused by mutated peroxisomal proteins, most prominently
in X-ALD or the Refsum syndrome. According to one view, oligodendro-
cytes with impaired peroxisomes fail to support white matter mainte-
nance. This is probably due to the peroxisomal failure to provide
oligodendrocytes with essential neuroprotective functions in order to
protect against axon degeneration and neuroinﬂammation [16]. This
conclusion is based on reports showing that peroxisomes may function
to inactivate reactive oxygen species (ROS) in cells, such as oligodendro-
cytes [17]. Nevertheless, peroxisomes may also be considered as a main
source of the generation of cellular ROS [18]. Moreover, a clear correla-
tion between enhanced tissue levels of VLCFA and inﬂammatory disease
progression in childhood X-ALD has been reported [19].
In addition, it has been claimed that oxidative stress is themajor fac-
tor in the pathogenesis of X-ALD [20–24]; and in mitochondrial perme-
ability transition pore (PTP) function [25]. Moreover, oxidative stress in
turn generates inﬂammatory responses of cytokine and chemokineme-
diators, thereby promoting generalized peroxisomal dysfunctions, and,
therefore, cell loss during the inﬂammatory demyelinating disease
[21]. Enhanced oxidative stress was found by different groups using
the X-ALD mouse model [24,26]. Moreover, C22:0, C24:0 and C26:0
were shown to induce neuronal damage by causing morphological
and functional changes in mitochondria of a human neuroblastoma
cell line [27]. Furthermore, ﬁbroblasts exposed to C26:0 exhibit en-
hanced generation of ROS, which is coupled with the decreased mito-
chondrial membrane potential (Δψm) [24]. Oxidative stress in X-ALD
has been documented as enhanced lipid peroxidation, reduced
plasmalogen level, and decreased antioxidant defense resulting in in-
creased GSSG/GSH ratio [20,26,28–32].
Therefore, an alternative strategy to reveal the role of VLCFA in the
pathogenesis of X-ALD is to analyze VLCFA-associated events triggering
the onset of X-ALD pathogenesis (see for recent reviews [33,34]).
ABCD1 gene expression in the brain of adult mouse and human is
mostly restricted to astrocytes, microglia cells, and oligodendrocytes
[35]. Dysfunction of ABCD1 in glial cells seems to have a special role in
the pathogenesis of X-ALD, since both oligodendrocytes and astrocytes
are important for myelination. Astrocytes inﬂuence the myelination
via secretion of factors or formation of cell–cell contacts to oligodendro-
cytes [36]. Furthermore, astrocytes are known to synthesize lipids and
supply these to other cells for myelination and synaptogenesis [37,38].
Previously, we could already demonstrate that excess of VLCFA is toxic
for neural cells, especially for glial cells [39,40]. In these studies we re-
vealed that VLCFA cause detrimental changes in hippocampal neurons,
astrocytes and oligodendrocytes by disturbing the intracellular Ca2+ ho-
meostasis and mitochondrial functions, which ﬁnally lead to death of
cells. The strongest impairment was seen in themyelin-producing oligo-
dendrocytes. However, until now no studies have been done concerning
the toxicity of VLCFA in neural cells of the Abcd1-knockoutmousemodel.
The degradation of VLCFA is orchestrated by the peroxisomal and
mitochondrial β-oxidation pathways (see for review [41]). This com-
bined degradation by both organelles is disturbed in X-ALD. From this
fact the important question arises: Does the biogenesis of mitochondria
respond to the defective ABCD1 protein, leading to mitochondrial func-
tions in the ABCD1-deﬁcient phenotype that are different from that of
the normal phenotype? Indeed, there are the following controversial re-
ports on alterations of mitochondrial functions in adrenoleukodystro-
phy. On the one side, structural abnormalities of mitochondria in cellsof X-ALD mice have been proposed to indicate impaired mitochondrial
functions [42,43], whereas on the other side it was reported that nor-
mality in size, structure and localization of mitochondria in muscle
can be detected in an ABCD1-deﬁcient mouse model for X-ALD [44].
Rates of oxygen uptake of phosphorylating isolated skeletal muscle mi-
tochondria from ABCD1-deﬁcient and wild-type mice also did not differ
[44]. In contrast, experiments with permeabilized spinal cord slices of
the ABCD1-deﬁcientmousemodel revealed a decrease of the phosphor-
ylating respiration by 20 to 25% [45]. This decrease in the phosphorylat-
ing respiration might be attributed to an oxidatively impaired FOF1-ATP
synthase activity [45] and/or to the noxious activity of an enhanced level
of VLCFA in the spinal cord slice tissue. The latter view is indicated by the
observation that the oligomycin-sensitive respiration of ﬁbroblast cul-
tures prepared from control ABCD1-deﬁcient mice (metabolizing galac-
tose) was similar, but decreased in the presence of 50 μM of C26:0 [45].
Moreover, reduced contents of mitochondria were found in neural tis-
sues from the spinal cords of the same mouse model [46].
Despite the fact that X-ALD is severely manifested in neural tissue,
most studies in the ﬁeld of X-ALD basic research were done using
Abcd1−/− ﬁbroblasts of patients or mice. Therefore, the present study
was designed to illuminate the inﬂuence of VLCFA accumulation on
glial cells of wild-type control mice and those from an X-ALD mouse
model (Abcd1−/−). Here, we investigated the inﬂuence of VLCFA on
the cellular properties of ROS production, variousmitochondrial param-
eters, cellular Ca2+ handling, and the reduction of a tetrazolium elec-
tron acceptor (WST-1) to the water-soluble formazan dye, and, ﬁnally,
induction of cell death in astrocytes.
Here, we report that astrocytes from wild-type control and ABCD1-
deﬁcient mice, which were exposed to supraphysiological concentra-
tions of the VLCFA (C22:0, C24:0 and C26:0) exhibit multiple impair-
ments of the astrocytic energy metabolism. In contrast, the functional
parameters of mitochondria from brain tissue of Abcd1−/− mice do
not differ from those of the wild-type control. This ﬁnding suggests
that a defective peroxisomal ABCD1 exerts no adaptive pressure on
the mitochondria. Moreover, mitochondria and astrocytes respond to
VLCFA with different lengths of the hydrocarbon chain in a different
manner, indicating that mitochondria are not the only target of detri-
mental VLCFA activities in astrocytes.
In summary, astrocytes from Abcd1−/−mice respond more sensi-
tively to VLCFA than those from wild-type control. Thus, long-term
application of VLCFA causes higher ROS generation and a stronger
in situ depolarization of mitochondria. In addition, VLCFA diminished
severely in Abcd1−/− astrocytes the capability to reduce the tetrazo-
lium electron acceptor (WST-1) to the formazan dye. Taken together,
these ﬁndings may help to establish new concepts for ﬁnding treat-
ments for X-ALD.
2. Materials and methods
2.1. Materials
Dulbecco'smodiﬁedEagle'smedium (DMEM), penicillin/streptomy-
cin and fetal calf serum (FCS) were obtained from Biochrom AG (Berlin,
Germany). The ﬂuorescent dyes Fura-2AM, dihydroethidium (DHE) and
Rhodamine 123 (Rh123) as well as Pluronic and the dead cell apoptosis
kit with annexin V FITC and propidium iodide (PI) were fromMolecular
Probes Invitrogen (Karlsruhe, Germany).Water-soluble tetrazolium salt
WST-1 was from Roche (Mannheim, Germany). Behenic acid (C22:0),
lignoceric acid (C24:0), and cerotic acid (C26:0) were obtained from
Larodan Fine Chemicals AB (Malmö, Sweden). All other chemicals
were from Sigma Aldrich (Taufkirchen, Germany).
2.2. Cell culture and treatment
All experiments with animals conformed to the guidelines of
Sachsen-Anhalt (Germany) on the ethical use of animals, and all efforts
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of newborn mice (C57BL6/Abcd1−/−, P1–P3), the meninges were re-
moved and the brains minced into small pieces using surgical scalpel.
Brain pieceswerewashed twicewith cold preparation buffer (low chlo-
ride PBS with modif-solution) and digested with 4 mg/ml trypsin type
XI for 7 min at 37 °C. Digestion was stopped by adding DMEM media
(supplemented with 10% FCS, 100 U/ml penicillin and 100 μg/ml strep-
tomycin). The digested tissue was washed again in preparation buffer
and afterwards triturated by passing the pieces through a Pasteur pi-
pette for several times. The cell suspension was ﬁltered by a tube-top
cell strainer (pore size 100 μm) and centrifuged for 5 min at 500 g.
After resuspending the cell pellet in culturemedia (DMEM supplement-
edwith 10% FCS, 100 U/ml penicillin, and 100 μg/ml streptomycin), cells
were plated onto cultureﬂasks and incubated by 37 °C and 10% CO2. The
medium was changed in intervals of two days and 24 h before the ex-
periment. Cells were used 14–20 days after plating. Possible contamina-
tion of the astrocyte cell preparations by microglia was estimated by
staining for the marker proteins GFAP and IB4, respectively. Resulting
micrographs displayed a low content of microglia in the astrocyte prep-
aration, amounting to less than 5% (not shown).
For the treatment of cells, VLCFA (C22:0, C24:0 and C26:0) were
dissolved in methanol/chloroform and further solubilized in α-
cyclodextrin solution (1 mg/ml) by soniﬁcation. α-Cyclodextrin so-
lution serves as vehicle, and was supplemented with an aliquot of
VLCFA-free methanol/chloroform mixture [47]. Pre-treatment of
cells was done by changing the culture medium with FCS to culture
medium without FCS and adding 20 μM or 40 μM of VLCFA for 24 h,
concentrations measured in human brain demyelinating plaques
(60 μM; [19]). For acute treatment, VLCFA were applied during the
measurements in the buffer used.2.3. Measurement of intracellular Ca2+ concentration,Δψm and ROS gener-
ation in living cells
All experiments of ﬂuorescencemicroscopy of living cells weremea-
sured with an imaging system (Agilent Technologies/TILL Photonics,
Gräfelﬁng, Germany) attached to a Zeiss Axioscope microscope (Carl
Zeiss, Jena, Germany). For measurements, cells were bathed in Hanks
balanced salt solution (HBSS: 5.44 mM KCl, 0.44 mM KH2PO4,
0.34 mM Na2HPO4, 0.49 mM MgCl2, 0.41 mM MgSO4, 132 mM NaCl,
10 mM HEPES, 5.56 mM glucose, 4.17 mM NaHCO3, 1.26 mM CaCl2)
which was completely exchanged within 0.5 min by a continuous
superfusion system. For measurements under Ca2+-free conditions,
Ca2+-free HBSS was prepared by omitting CaCl2 and supplementing
0.6 mM EGTA. The substances tested were applied to the superfusate
via a syringe pump. All experiments were performed with solutions
kept at 36 °C.
For measurement of the intracellular Ca2+ level, cells were loaded
with the Ca2+-sensitive ﬂuorophore Fura-2AM (2 μM, 0.02% Pluronic)
for 30 min at 22 °C. By the cleavage of unspeciﬁc esterase activity the
dye remains intracellular after loading and is able to bind free Ca2+.
Fluorescence signals were detected every 3 s at 510 nm emission by al-
ternate excitation at 340 nm (bound to Ca2+) and 380 nm (unbound
Fura-2). The intracellular amount of Ca2+ released was calculated by
the ratio of the ﬂuorescence intensities obtained at 340 nm and
380 nm in regions of interests covering intracellular space of cells.
To estimateΔψm, cellswere loadedwith the cationic dye Rhodamine
123 (Rh123, 5 μM, 30min)which accumulates in themitochondrialma-
trix of energized mitochondria and afterwards incubated with test sub-
stances for 5 min. Fluorescence was detected at 590 nm by excitation at
520 nm [48]. Rh123 accumulated inmitochondriawasmeasured via the
increase of Rh123 ﬂuorescence over the mitochondria-free nucleus of
cells after depolarization evoked by combined application of the
uncoupler carbonyl cyanide 4-triﬂuoromethoxyphenylhydrazone
(FCCP, 4 μM) and the FOF1-ATPase inhibitor oligomycin (10 μM). TheFCCP/oligomycin-mediated depolarization and therefore Rh123 release
under control conditions was taken as 100%.
The generation of ROS was carried out by the oxidation of
dihydroethidium (DHE, 1 μM) to the ethidium cation, which binds to
nuclear DNA. For measuring ROS production the dye was applied to-
gether with the test substances directly to the cells and excited at
520 nm with emission at 590 nm.
2.4. Isolation of mitochondria, ﬂuorimetric and oxygraphic measurements
Mitochondria were prepared from the brains of 6month old C57BL6
wild-type and Abcd1−/−mice and kept at a temperature of 4 °C. After
removal, the brains were washed in ice-cold NaCl solution (0.9%) and
afterwards homogenized in isolation buffer (320 mM sucrose, 10 mM
Tris/HCl, 0.5 mM EDTA, 0.5 mM EGTA, 0.5% BSA, pH 7.4). The homoge-
nate was centrifuged at 2000 g for 4 min. The pellet of mitochondria
was obtained by centrifugation of the supernatant at 2000 g for 4 min
and thereafter at 12,000 g for 11 min. To purify mitochondria, a Percoll
gradient (10%, 15%, 24%) was used and afterwards the mitochondria
were washed in wash buffer (320mM sucrose, 10mM Tris/HCl, pH 7.4).
Generation of ROS in isolated mitochondria was determined by
oxidation of non-ﬂuorescent Amplex Red to ﬂuorescent Resoruﬁn
monitored by the Perkin-Elmer Luminescence spectrometer LS 50
(excitation at 560 nm, emission at 590 nm). Therefore, mitochondria
(0.2 mg/ml) were kept in incubation buffer (125 mM KCl, 10 mM
Tris/HCl, 5 mM KH2PO4, pH 7.4) supplemented with Amplex Red
(5 μM), succinate/glutamate (5 mM), horseradish peroxidase (2 U/
ml) and superoxide dismutase (10 U/ml). Treatment of mitochon-
dria with test substances was started after 5 min of reverse electron
transport-(RET)-mediated ROS formation [49,50] for a time period of
10 min. In addition, ROS generated by the forward electron transport
(FET) was also measured with the Amplex Red assay. In this case, mi-
tochondria were supplied with glutamate plus malate (5 mM each)
as substrates. The ﬂuorescence signal of Resoruﬁn was calibrated
by sequential additions of known amounts of H2O2 (up to 75 pmol).
Ca2+ uptake and release from isolated mitochondria were assayed
using the ﬂuorescent dye Calcium Green-5N (CaG5N). Mitochondria
(0.5 mg/ml) were incubated in incubation buffer containing malate
(5mM), glutamate (5mM) andCaG5N (0.1 μM) andwere treated by in-
cremental intermittent pulses (20 nmol CaCl2/mg of protein) of CaCl2-
containing stock solution (2 mMCaCl2) until the PTP opened. Resulting
changes in Ca2+ concentration in the incubation buffer were detected
by CaG5N ﬂuorescence using wavelengths for excitation and emission
of 506 nm and 532 nm, respectively.
Mitochondrial respiration was measured using an Oroboros Instru-
ments Oxygraph® (Innsbruck, Austria) at 37 °C. For this purpose, isolat-
edmitochondria (0.5mgof protein perml)were suspended in standard
incubation medium supplemented with glutamate plus malate (5 mM
each) as substrates.
2.5. Assay of cell death
For the determinationof themechanismof cell death, the challenged
cells were incubated with the VLCFA C22:0, C24:0 and C26:0 (40 μM) in
culture medium (without FCS) for 24 h and afterwards stained with
FITC annexin V and PI for 15 min. Stained cells were detected with a
Zeiss LSM 510 META confocal laser scanning microscope with the re-
spective ﬁlters for the ﬂuorescence excitation/emission maxima (FITC
annexin V: 494 nm/518 nmand PI: 535 nm/617 nm). For quantiﬁcation,
the number of FITC annexin V- and PI-stained cells was calculated in
correlation to the total cell number.
2.6. Reduction of tetrazolium electron acceptor WST-1
To assess the reducing capability of VLCFA-treated astrocytes, cells
were exposed to thewater-soluble,membrane-impermeable tetrazolium
Fig. 1. VLCFA-induced formation of reactive oxygen species (ROS) in primary astrocytes.
Generation of ROSwas detected by the oxidation of dihydroethidium(DHE) to ﬂuorescent
ethidium cation which binds to DNA. DHE (1 μM) was applied to the cells during the
measurement in combination with the fatty acids C22:0, C24:0 and C26:0 (all at a
concentration of 40 μM) for 25min. To analyze long-term effect of VLCFA on ROS genera-
tion, cellswere pre-treatedwith 20 μMof C22:0, C24:0 and C26:0 for 24 h and additionally
during the measurement with 40 μM of the VLCFA (hatched bars). Ethidium cation ﬂuo-
rescence was normalized to wild-type control (contr; α-cyclodextrin 1 mg/ml, similarly
for Figs. 3–6, and 9; dashed line = 1). Data represent mean values ± SEM of at least
three different experiments and preparations. *p b 0.05 compared to Wt control,
#p b 0.05 for comparisons indicated by respective lines.
Fig. 2. Lipid peroxidation in wild-type (Wt) and Abcd1−/− astrocytes. Lipid peroxidation
was analyzed by the level of thiobarbituric acid reactive substances (TBARS) given in
nmol malondialdehyde/mg of protein in cell lysates of untreated astrocytes. Values
shown represent mean values ± SEM of ﬁve different experiments.
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2H-tetrazolium) plus 1-methoxy phenazine methosulphate [51]. The
latter mediates the electron transport from the cytosolic, and reduced
pyridine nucleotides (NAD(P)H) to the extracellular tetrazolium salt.
Thereby, the pale-colored tetrazolium salt becomes converted into a
deep-colored-formazan dye.
Primary astrocytes seeded at a density of 5 × 104 cells/well into 96-
well culture plates were treated with various VLCFA concentrations
(10 μM, 20 μM and 40 μM) in culture media without FCS. After incuba-
tion for 24 h, an aliquot of WST-1 reagent (diluted 1:10) was added to
each well and after additional 4 h of incubation, the absorbance
(450 nm) of the formed formazan dye was measured.
2.7. Thiobarbituric acid reactive substances (TBARS) assay
Lipid peroxidation was determined by TBARS formation. Brieﬂy,
100 μl of samples was incubated with 250 μl of 0.36% thiobarbituric
acid (in 20% acetic acid, pH 3.5) at 95 °C for 60 min. The mixture was
allowed to cool down on ice for 5 min and was then centrifuged at
1100 g for 15 min. The pink-stained TBARS in the supernatant was de-
termined at 532 nm absorbance. A calibration curve was established
using a malondialdehyde (MDA) standard. TBARS was given as equiva-
lent of nmol MDA/mg of protein.
2.8. Statistical analysis
All data are represented asmean±SEMof at least three different ex-
periments and preparations. For statistical analysis Student's t-test was
used. A p value less than 0.05 was considered as statistically signiﬁcant
(p b 0.05).
3. Results
3.1. VLCFA increase the generation of reactive oxygen species (ROS) of as-
trocytes and enhance the oxidative stress
Several reports demonstrate increased oxidative stress in tissues of
X-ALD patients [52,53]. Therefore, we studied ﬁrst the intracellular
ROS formation in astrocytes from a X-ALD mouse model (Abcd1−/−)
and wild-type mice, treated with 40 μM VLCFA. We used the ROS-
sensitive probe DHE. Fig. 1 shows that the ROS formation in wild-type
cells was increased, when cells were treated with C22:0 (1.4-fold),
C24:0 (1.5-fold) and C26:0 (2.0-fold). All our data obtained are referred
to that of the control condition (indicated as the dashed line),where the
astrocyteswere treated onlywith the vehicleα-cyclodextrin (1mg/ml).
Comparable results were achievedwith Abcd1−/− cells, indicated as 1.3-,
1.4-, and 2.3-fold increase of ROS production with C22:0, C24:0 and
C26:0, respectively. ROS generation was most strongly enhanced with
C26:0, but the increase was signiﬁcantly higher in Abcd1−/− cells than
in wild-type cells.
Accumulation of VLCFA in patients suffering from X-ALD persists
over long time periods. Along this line, we next analyzed the effect of
longer-term application of VLCFA (24 h incubation with 20 μM before
measurement with 40 μM VLCFA) on the ROS generation. In pre-
treated wild-type astrocytes, the amount of cellular ROS production
remained almost unchanged as compared to the short-term exposure
to VLCFA, whereas pre-treatment of Abcd1−/− astrocytes with VLCFA
strongly enhanced the ROS formation (Fig. 1). The amount of ROS pro-
duced in pre-treated Abcd1−/− astrocytes was for C22:0, C24:0 and
C26:0 about 3-fold above the control value. Clearly, pre-treatment of
Abcd1−/− cells resulted in a stronger increase in ROS generation as com-
pared to astrocytes with only acute application of VLCFA (2.3-fold with
C22:0, 1.9-fold with C24:0 and 1.4-fold with C26:0).
Moreover, even in the absence of added VLCFA, Abcd1−/− cells
were obviously more sensitive to oxidative stress, as suggested
by enhanced lipid peroxidation. Thus, the level of measured TBARS(thiobarbituric acid reactive substances) in Abcd1−/− astrocytes was
2.04 ± 0.35 nmol/mg of protein compared with 1.18 ± 0.21 nmol/mg
of protein in wild-type astrocytes (Fig. 2).
3.2. VLCFA reduce the membrane potential of mitochondria in astrocytes in
situ
For studying the inﬂuence of VLCFAon themitochondrialmembrane
potential (Δψm) under in situ conditions, wild-type and Abcd1−/− astro-
cytes were loadedwith the cationic ﬂuorescent dye Rh123, which accu-
mulates in the mitochondrial matrix. Then we treated the cells with
40 μM of the VLCFA C22:0, C24:0 and C26:0 for 5 min. Thereafter, the
Rh123 content in mitochondria was evaluated by adjusting the
complete collapse of Δψm with the uncoupler carbonyl cyanide 4-
triﬂuoromethoxyphenylhydrazone (FCCP, 4 μM) plus the FOF1-ATPase
inhibitor oligomycin (Oli, 10 μM). Oli was added to prevent a possible
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hydrolysis of glycolytically formed ATP. As previously reported [48],
the amount of releasable Rh123 is reciprocally related to deenergizing
activity of a mitochondrial poison. Moreover, the estimated Δψm,
whichwas observedwhenwild-type astrocyteswere exposed to the ve-
hicle α-cyclodextrin (1 mg/ml as solvent control) was taken as control
(given as 100%; Fig. 3, dashed line). With respect to this control, Δψm
was slightly lower in Abcd1−/− cells.
From Fig. 3 it can be clearly seen that the treatment of astrocytes
with VLCFA decreased the amount of FCCP/Oli-releasable Rh123 dye.
This indicates the sensitivity of Δψm to VLCFA. For illustration, with re-
spect to C26:0, inwild-type cellsΔψm is decreased by 43%±3.4,where-
as in Abcd1−/− cells the change in Δψm was only 26% ± 3.4. Observed
changes in Δψm with C22:0 (wild-type cells 25% ± 3.9; Abcd1−/− cells
28% ± 3.1) and C24:0 (wild-type cells 26% ± 2.8; Abcd1−/− cells
30% ± 3.5) are similar in wild-type cells and Abcd1−/− cells.
Surprisingly, in pre-treated wild-type cells (24 h incubation of cells
with 20 μM of VLCFA), addition of 40 μM VLCFA increased the release
of Rh123. This clearly suggests that the pre-treatment exerts a stabiliz-
ing effect on Δψm against VLCFA (Fig. 3). In contrast, in Abcd1−/− cells
pre-treatment with C22:0 or C24:0 resulted in a potentiated decrease
of the Δψm up to 40% ± 2.6 and 39% ± 2.6, which is statistically signif-
icantly different from the decrease detected without pre-treatment
(28% ± 3.1 and 30% ± 3.5). Pre-treatment with C26:0 was without ef-
fect on the Rh123 release, as seen after the subsequent addition of
40 μM C26:0 Abcd1−/− cells.3.3. VLCFA directly affect the inner membrane of isolated brain
mitochondria
It is quite likely that the decrease ofΔψm shown in Fig. 3 results from
the protonophoric activity of VLCFA and, in addition, from a partial de-
regulation of the electron transport chain by VLCFA (most likely for
C24:0 or C26:0) [54]. To verify further a direct inﬂuence of VLCFA on
the inner mitochondrial membrane (IMM), we studied the effect ofFig. 3.Mitochondrial membrane potential (Δψm) in astrocytes: Effect of very long chain
fatty acids (VLCFA) on the Δψm, quantiﬁed as release of Rh123 from mitochondria under
in situ accumulation. Cellswere incubatedwith theVLCFAC22:0, C24:0 and C26:0 at a con-
centration of 40 μMand as control withα-cyclodextrin (1mg/ml) for 5min. Hatched bars
represent cells pre-treatedwith 20 μMof VLCFA for 24 h. The bars showΔψm given by the
Rh123 release obtained after the combined application of the uncoupler FCCP (4 μM) and
the FOF1-ATPase inhibitor oligomycin (10 μM). Thismethod has been described previously
[48]. Values are given in percent of thewild-type control value (dashed line=100%). Data
represent mean values ± SEM of at least three different experiments. *p b 0.05 compared
to wild-type control (100%), #p b 0.05 for the comparisons indicated by respective lines.VLCFA on the electron transport chain associated ROS generation with
isolated mouse brain mitochondria (MBM). We investigated ﬁrstly
with MBM the effect of VLCFA on ROS generation, which is associated
with the forward electron transport (FET). This was done by ﬂuorimet-
ric recording of the H2O2 released from respiring MBM into the incuba-
tion medium using the Amplex Red assay. To analyze the inﬂuence of
VLCFA on ROS production by FET, the slope of the increase of Resoruﬁn
ﬂuorescence obtained after addition of VLCFA was referred to the slope
recorded in the absence of VLCFA (Fig. 4A).With respect to the ROS gen-
eration and its modulation by VLCFA, no signiﬁcant difference between
theMBM fromwild-type and Abcd1−/−micewas found (Fig. 4B).More-
over, a signiﬁcant increase in the FET-associated H2O2 release was de-
tectable only with C22:0-treated mitochondria, both from wild-type
and Abcd1−/− mice (2.6-fold and 2.7-fold above control), whereas
C24:0 and C26:0 showed almost no effect on the FET-associated H2O2
release.
Since the ROS production connectedwith the reverse electron trans-
port (RET) responds very sensitively to the decrease of Δψm, we deter-
mined, in addition, the possible effect of VLCFA on the H2O2 release
supported by RET. For that,MBMwere suppliedwith succinate plus glu-
tamate and the released H2O2wasmeasured in the absence or presence
of VLCFA. It is an important feature of isolated neuronal mitochondria
that the succinate dehydrogenase is inhibited by endogenous oxaloace-
tate [55]. Therefore, glutamate was added to remove oxaloacetate by
transamination to aspartate. This avoids any inhibition of succinate de-
hydrogenase during succinate oxidation.
Oxidation of succinate by complex II of the electron transport chain
builds up a high Δψm, which enables the uphill transport of the elec-
trons from complex II to complex I. Consequently, a depolarization of
the IMM leads to a reduction of the RET-supported ROS production, as
we have reported before [50,54]. The data obtained are summarized in
Fig. 4C. The vehicle α-cyclodextrin had no effect on ROS production
and was used as control. Similar to the FET-dependent ROS production,
only C22:0 exerts a strong effect on the RET-based ROS production. This
effect was not signiﬁcantly different between MBM of wild-type mice
(C22:0 29% ± 2) and Abcd1−/−mice (C22:0 33% ± 12). The uncoupler
FCCP evoked an almost complete reduction of RET-dependent ROS pro-
duction with remaining 9% ± 2 (Wt) and 14% ± 2 (Abcd1−/−).
The different effects of VLCFA on the FET- and RET-dependent ROS
production are also reﬂected in their inﬂuence on the rate of the elec-
tron transport in the IMM, indicated as change of the resting respiration.
Thus, the rate of the resting respiration of wild-type MBM shows that
the addition of C22:0 to MBM supplied with glutamate plus malate
as hydrogen-delivering substrates, stimulates the resting respiration
about 2-fold, clearly indicating the depolarization of the IMM
(Fig. 5A). In comparison to C22:0, stimulation of the resting respiration
by C24:0 is much lower, and absent for C26:0 additions. Moreover,
when FCCP was added in the absence of VLCFA, the increase of the rest-
ing respiration was high. Remarkably, a subsequent addition of C22:0
decreased the FCCP-uncoupled respiration, indicating the ability of
VLCFA to de-regulate the electron transport.
In addition, the effect of VLCFA was examined on the ADP-stimulated
respiration (state 3) of MBM isolated fromwild-type and Abcd1−/−mice.
Both types ofmitochondria exhibit a high rate of ADP-dependent respira-
tion, with no signiﬁcant difference between wild-type and Abcd1−/−
mice. Even in the case of mitochondria isolated from one-year-old
Abcd1−/−mice, state 3 respiration is similar to that seen in mitochondria
from adult wild-type mice (Table 1). From Fig. 5B it can be seen that
VLCFA inhibit as a function of the hydrocarbon-chain length the state 3-
respiration in both types of mitochondria. In contrast, the vehicle (α-cy-
clodextrin) was nearly without effect (data not shown).
Taken together, C22:0 exerts the strongest effects on MBM, clearly
indicated as mild uncoupling of the resting respiration and the inhibi-
tion of the FCCP-uncoupled or state 3-respiration. These ﬁndings clearly
reveal pronounced effects of C22:0, ﬁrst the decrease of Δψm and sec-
ond, a partial impairment of electron transport to oxygen.
Fig. 4. Inﬂuence of VLCFA on themitochondrial ROSproduction. Brainmitochondria isolat-
ed fromwild-type and Abcd1−/−mice,were suspended in incubation buffer (125mMKCl,
10mMTris/HCl, 5mMKH2PO4, pH7.4) supplementedwith AmplexRed (5 μM), horserad-
ish peroxidase (2 U/ml) and superoxide dismutase (10 U/ml) thermostated to 37 °C.
(A) Traces of the recordings of the resoruﬁn ﬂuorescence generation by forward electron
transport (FET)-driven H2O2 release. For measuring the H2O2 release dependent on FET,
the medium contained 0.4 mg of protein/ml and glutamate plus malate (5 mM/5 mM)
as substrates. Rates of the H2O2 release are expressed as pmol H2O2/min∗mg of protein
above the traces of mitochondria from wild-type mice. Incorporated in panel A is calibra-
tion of the Resoruﬁn ﬂuorescence using external H2O2. (B) Summarized data of the FET-
dependent release of H2O2. For analysis the ratio of the slope of the Resoruﬁn ﬂuorescence
after application of VLCFA (16 μM, corresponding to 40 nmol/mg of protein) and the slope
detected with the vehicle α-cyclodextrin (1 mg/ml, control) was calculated. ROS genera-
tion of untreated mitochondria from wild-type or Abcd1−/−mice corresponds to 194 ±
78H2O2 pmol/min/mg of protein or 160± 41H2O2 pmol/min/mg of protein, respectively.
(C) H2O2 release, depending on the reverse electron transport (RET). RET ofmitochondria
(0.2 mg of protein/ml) was measured in medium containing succinate plus glutamate
(5 mM/5 mM) as substrate. Additions were: the vehicle α-cyclodextrin (1 mg/ml, con-
trol), VLCFA (8 μM, corresponding to 40 nmol/mg of protein) and FCCP (0.05 μM). Data
shown are mean values ± SEM obtained from three preparations of mitochondria from
wild-type and from Abcd1−/−mice. *p N 0.05 compared to the corresponding control α-
cyclodextrin.
Fig. 5. Effect of VLCFA on the mitochondrial respiration. Oxygen uptake was measured in
brain mitochondria from wild-type mice and Abcd1−/−mice (0.5 mg of protein/ml) in in-
cubation buffer supplemented with glutamate plus malate (5 mM/5 mM) as substrates.
Panel A shows the effect of VLCFA (C22:0, C24:0 and C26:0 (each 27 μM, corresponding
to about 50 nmol/mg of protein)) on the resting respiration and that of C22:0 on the
FCCP-uncoupled respiration. In the latter case,mitochondriawere suppliedwith succinate
plus glutamate (5 mM/5mM) as substrates. FCCPwas given to mitochondria at a concen-
tration of 0.05 μM. Panel B shows the effect of VLCFA on state 3 respiration. For this, ADP
(1.3 mM) was applied to mitochondria in addition to the VLCFA. Data shown in panels A
and B are mean values ± SEM obtained with 3 or 5 mitochondrial preparations.
*p N 0.05 compared to the corresponding control α-cyclodextrin (panel A) and ADP
(panel B). #p b 0.05 for comparison indicated by respective line.
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The results above show that VLCFA permeabilize the IMM to H+ and
impair the electron transport. Therefore, we next examined their inﬂu-
ence on the energy-dependent Ca2+ uptake by MBM. Their ability to
take up extra-mitochondrial Ca2+ from the incubation medium into
the matrix compartment is the so-called Ca2+ retention capacity
(CRC). The phase of overriding the CRC initiates the opening of the per-
meability transition pore (PTP) and Ca2+ efﬂux occurs [56–58]. Experi-
mentally the CRC was determined by repeated, incremental pulses of
CaCl2-containing stock solution to the incubation mixtures with MBM
(Fig. 6A). CaCl2 pulses ﬁrst increase the ﬂuorescence signal of the
extra-mitochondrial Ca2+ indicator Calcium Green-5N (CaG5N),
which thereafter due to Ca2+ sequestering by mitochondria returns toTable 1
Rates of respiration of brain mitochondria from adult wild-type (5months old) and one-
year-old Abcd1−/−mice. Results are shown as mean values for rates of respiration (nmol
O2/min/mg of protein) ± standard deviation (n = 4).
WT mice ABCD1−/−mice
Rates of respiration (nmol O2/min/mg of protein)
Resting State 3 Resting State 3
+ADP 24 ± 3 113 ± 7 19 ± 3 104 ± 23
+ADP + C22:0 22 ± 4 88 ± 19 20 ± 8 100 ± 20
+ADP + Cyclo 20 ± 6 111 ± 11 19 ± 1 104 ± 31
Fig. 6. Effect of VLCFA on the Ca2+ retention capacity of brainmitochondria. Mitochondria
(0.5mg/ml) of wild-type and Abcd1−/−micewere suspended in incubationmedium sup-
plemented with the ﬂuorescent Ca2+ indicator Calcium Green-5N (CaG5N, 0.1 μM) and
malate (5 mM) and glutamate (5 mM) as respiratory substrates. (A) Typical traces of
changes in Ca2+ concentration monitored by CaG5N-ﬂuorescence in the medium after
pulses of CaCl2 (20 nmol/mg of protein). Application of C22:0, C24:0 and C26:0 (40 and
80 nmol/mg of protein = 20 and 40 μM)was done 1 min before the ﬁrst CaCl2 pulse (in-
dicated by arrows). (B) Quantitative analysis of the Ca2+ retention capacity. The sum of
CaCl2 pulses prior to PTP opening was calculated as the Ca2+ retention capacity and was
normalized to the Ca2+ concentration obtained in mitochondria from wild-type mice
under control conditions (α-cyclodextrin, 1 mg/ml, dashed line) = 100%. Values shown
are mean values ± SEM of at least three different mitochondria preparations. *p b 0.05
compared to the correspondingwild-type and Abcd1−/− control, #p b 0.05 comparison be-
tween wild-type and Abcd1−/− are indicated by respective lines.
Fig. 7. Effect of VLCFA on the intracellular Ca2+ homeostasis in astrocytes. (A) Kinetics of
Ca2+ responses in cells due to acute application of C26:0 (40 μM). Ca2+ increases marked
by dashed lines show responses from cells which were pre-treated for 24 h with 20 μMof
C26:0. Horizontal line indicates the acute application time period of the fatty acid. Fura-
2AM ﬂuorescence ratio R (F340/F380)was normalized to the initial ratio (R0) detected be-
fore treatment of cells. (B) Quantitative analysis of theVLCFA-inducedmaximal intracellu-
lar Ca2+ increase inWt and Abcd1−/− astrocytes in comparison to the Ca2+ rise in cells
treated with the vehicle α-cyclodextrin (1 mg/ml). Hatched bars represent results from
cells pre-treated with 20 μM of VLCFA for 24 h. Data represent mean values ± SEM of at
least three different experiments. *p b 0.05 compared to control α-cyclodextrin (dashed
line). #p b 0.05 for the comparisons indicated by respective lines.
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sudden increase in CaG5N ﬂuorescence, resulting from the opening of
PTP (Fig. 6A).
Interestingly, mitochondria from Abcd1−/− mice showed slightly,
but signiﬁcantly higher CRC than those from wild-type mice(Abcd1−/− with 125% ± 4.2 compared to wild-type with 100% ± 6.6;
see analysis in Fig. 6B). Application of the VLCFA C22:0, C24:0 and
C26:0 (40 and 80 nmol/mg protein corresponding to 20 and 40 μM)
caused inMBM fromwild-type and Abcd1−/−mice a general premature
opening of the PTP, quantiﬁed by lowering of the CRC (Fig. 6B). Again,
the strongest effect was found with C22:0 (80 nmol/mg protein),
where the reduction was 32% ± 3.6 in wild-type and 48% ± 3.6 in
Abcd1−/−mitochondria. Thus, VLCFA diminish the CRC by sensitization
MBM for PTP opening. However, even in the presence of VLCFA, CRC is
higher in ABCD1−/−MBM compared to controls. Taking into consider-
ation that VLCFA depolarize control and ABCD1−/− MBM similarly
(Fig. 3), a lower VLCFA-linked decrease of CRC in ABCD1−/− MBM
may indicate that VLCFA delay the opening of PTP.
3.5. VLCFA-induced intracellular Ca2+ response is diminished in Abcd1−/−
astrocytes
Besides their involvement in pathways leading to cell death and cel-
lular ROS production, mitochondria also play an important role in Ca2+
signaling and storage. Asmentioned above,we found thatmitochondria
of Abcd1−/−mice exhibit a slightly higher CRC than mitochondria from
wild-type mice (Fig. 6). Therefore, we made a comparative analysis of
the inﬂuence of C22:0, C24:0 and C26:0 on changes in the cytosolic
Ca2+ level in astrocytes. Representative traces in Fig. 7A depict the
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tracellular Ca2+ level in wild-type astrocytes. Application of VLCFA to
Abcd1−/− astrocytes resulted also in a signiﬁcant intracellular Ca2+ re-
sponse. The intracellular Ca2+ rise induced byVLCFA in rat hippocampal
co-cultures of neurons, astrocytes, and oligodendrocytes was already
described by us previously [39].
In the study presented here, the comparative analysis of the maxi-
mal intracellular Ca2+ level reached in wild-type and Abcd1−/− astro-
cytes after acute application of VLCFA revealed differences between
both types of cells. Surprisingly, themaximal intracellular Ca2+ increase
in wild-type astrocytes was higher than that in Abcd1−/− astrocytes
with C22:0 1.4-fold, C24:0 1.8-fold and C26:0 2.2-fold, as given in the
statistical analysis in Fig. 7B. This difference was signiﬁcant for all fatty
acids. These results indicate that the intracellular Ca2+ signaling path-
way activated by VLCFA in astrocytes of Abcd1−/−mice is disturbed. It
is conceivable that mitochondria buffer the intracellular released Ca2+
leading to a lower Ca2+ rise in Abcd1−/− cells.
Moreover, pre-treatment of astrocytes with VLCFA (20 μM for 24 h)
potentiated the effect of acute VLCFA application in wild-type and
Abcd1−/− cells. The intracellular Ca2+ responses increased dramatically
in these cells compared to the Ca2+ responses in cells which were not
pre-treatedwith the VLCFA (Fig. 7B). To further analyze the discrepancy
of the reduced maximal intracellular Ca2+ rise in Abcd1−/− astrocytes
after acute VLCFA exposure we studied the Ca2+ load of intracellularFig. 8. Ca2+ store content and capacitative Ca2+ inﬂux in astrocytes after store depletion
by SERCA inhibitor cyclopiazonic acid (CPA). Intracellular Ca2+ changes are presented as
ﬂuorescence ratio R (340/380) in Fura-2AM loaded cells. (A) Kinetic of CPA-induced
store depletion under Ca2+-free conditions and the following store-operated Ca2+ entry
due to re-addition of Ca2+-containing buffer. Capacitative Ca2+ inﬂux was determined
by measuring the amplitude of the intracellular Ca2+ increase after the addition of
Ca2+-containing buffer. (B) Quantitative analysis of store content analyzed by depletion
with CPA (10 μM) and subsequent capacitative Ca2+ inﬂux. Data are mean values ±
SEM of at least three different experiments.Ca2+ stores. Therefore, the sarcoplasmic–endoplasmic reticulum
Ca2+-ATPase inhibitor cyclopiazonic acid (CPA, 10 μM) was used in
Ca2+-free buffer to induce store depletion. The example trace in
Fig. 8A illustrates the method. The content of Ca2+ stores in the cells is
indicated by the amplitude of the intracellular Ca2+ increase due to
CPA application. The Ca2+ rise after the extracellular addition of Ca2+
to the Ca2+-free medium demonstrates the store-operated Ca2+ inﬂux
in the cells. The intracellular Ca2+ level reached after CPA-induced store
depletion in Abcd1−/− astrocytes does not signiﬁcantly differ from the
Ca2+ level in wild-type cells, as can be seen in Fig. 8B. Furthermore,
no difference could be detected betweenwild-type and Abcd1−/− astro-
cytes regarding the capacitative Ca2+ inﬂux caused after intracellular
Ca2+ store depletion. The possible reasons for the reduced VLCFA-
mediated intracellular Ca2+ response in the Abcd1−/− cells (Fig. 7) are
considered in the discussion.
3.6. Effects of VLCFA on the regeneration of reduced pyridine nucleotides
(NAD(P)H) by astrocytes
The survival of cultured cells can be determined by measuring the
reductive conversion of the tetrazolium-electron acceptor to a formazan
dye, which absorbs at 450 nm. Tetrazolium reduction depends on the
activity of NAD(P)H-linked oxidoreductases, which largely operate in
the cytosolic compartment of the cells [51]. Tetrazolium-reduction
was used to examine the impairment of the regeneration of reduced
pyridine nucleotides in VLCFA-treated astrocytes. The assay is based
on a water-soluble and membrane-impermeable tetrazolium salt
(WST-1) and uses 1-methoxy phenanzine methosulphate as mediator
to shuttle electrons from cytosolic NAD(P)H across the plasma mem-
brane to the electron acceptor WST-1. Consequently, WST-1 reduction
reﬂects the rate of conversion of the cellular oxidized pyridine nucleo-
tides into their reduced form (NAD(P)H). Rates of WST-1 reduction by
astrocytes, which were pretreated with supraphysiological concentra-
tions of VLCFA, are shown in Fig. 9. The data clearly reveal that in
VLCFA-treated ABCD1−/− astrocytes, the ability to regenerate
NAD(P)H is lower. In addition, C24:0 and C26:0, even at the lowest con-
centration applied (10 μM), have a more pronounced effect than C22:0.
In addition, brain mitochondria isolated fromWT and ABCD1−/−mice
do not differ in their ability to reduce the tetrazolium salt (data not
shown). This was measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-Fig. 9. Effect of VLCFA treatment on tetrazolium salt (WST-1) reduction of astrocytes. As-
trocytes of Abcd1−/− and wild-type mice were stimulated with various concentrations
(10 μM, 20 μM and 40 μM) of the VLCFA C22:0, C24:0 and C26:0 for 24 h. Then we deter-
mined after 4 h the WST-1 reduction. Values are given in percent of the corresponding
wild-type or Abcd1−/− control values (=100%) achieved with α-cyclodextrin (1 mg/ml).
Data represent mean values ± SEM of at least three different experiments. #p b 0.05 for
the comparisons indicated by respective lines.
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mental activity on the pyridine nucleotide regeneration largely in the
cytosolic compartment.
3.7. VLCFA induce apoptosis in astrocytes
Opening of the PTP is the precondition of the mitochondria-guided
apoptosis. Thus, we tested whether VLCFA initiate the apoptosis in as-
trocytes. We measured the release of the cytosolic lactate dehydroge-
nase into the medium. 24 h incubation with 40 μM of VLCFA evoked a
signiﬁcant lactate dehydrogenase release inwild-type and Abcd1−/− as-
trocytes. This therefore indicates the toxic activity of the C22:0, C24:0
and C26:0 on neural cells (data not shown). Furthermore, the mecha-
nism of VLCFA-induced cell death was studied in detail via annexin V
and PI staining in Abcd1−/− astrocytes after 24 h incubation with the
fatty acids. We found that most of the ﬂuorescence-marked cells were
stained with annexin V (columns marked with hatching; C22:0, 80%;
C24:0, 94%; C26:0, 84% of stained cells), which indicates the apoptotic
route of cell death. Only a small portion exhibited PI ﬂuorescence
(columns marked with crossings), reﬂecting necrosis (Fig. 10).
4. Discussion
Since X-ALD is a neurodegenerative disease, we used astrocytes and
isolated brain mitochondria from Abcd1-knockout mice in our studies.
While ABCD1 expressionwas shown for astrocytes,microglia, oligoden-
drocytes and neurons [35,59], most studies published on the detrimen-
tal activity of VLCFA in tissues were made with Abcd1−/− ﬁbroblasts.
Here we addressed particularly the question whether the energy me-
tabolism has vulnerability to exposure to VLCFA C22:0, C24:0 and
C26:0 in wild-type astrocytes (control) and those prepared from the
brain of an ABCD1-deﬁcient mouse model. The C26:0 VLCFA is up to
4–6-fold enhanced in patients suffering from X-ALD [2]. The concentra-
tions of applied VLCFA (20 and 40 μM) are comparable to those used in
other studies [31,39].
Furthermore, there is an ongoing debate on mitochondrial abnor-
malities in X-ALD and other peroxisomal disorders, like Zellweger
syndrome [42,60–62]. This interest is supported by the cooperation of
mitochondria and peroxisomes in the degradation of VLCFA [41]. Thus,
a defective peroxisomal β-oxidation in Abcd1−/− cells raises theFig. 10. Cell death induced by VLCFA in Abcd1−/− astrocytes. Cells were treated with
C22:0, C24:0, C26:0 (all 40 μM) and α-cyclodextrin (1 mg/ml) as control for 24 h and af-
terwards stained with annexin V (for apoptotic cell death) and propidium iodide (PI, for
necrotic cell death). For analysis, cells were counted by their annexin V- and PI-staining.
Number of dead cells (annexin V- and PI-positive) was calculated as percentage of total
cell number. Values obtained under control conditions (treatment with α-cyclodextrin)
were subtracted from the values obtained with VLCFA-treated cells. Data are mean
values± SEM of at least three different experiments and cell preparations. *p b 0.05 com-
pared to controlα-cyclodextrin. #p b 0.05 for comparison between apoptotic and necrotic
cell death indicated by lines.question, whether mitochondria display a compensatory response to
the peroxisomal defect. For that reason, we focused our attention also
on possible alterations of mitochondrial parameters (ROS generation,
state 3 respiration, CRC, and Δψm) in mitochondria prepared from the
brain tissue of the ABCD1-deﬁcient mouse model.4.1. Deleterious activities of VLCFA and sensitivity to VLCFA in brain cells
from aged Abcd1−/− animals
To uncover possible differences in the responses of wild-type and
Abcd1−/− astrocytes to VLCFA, two incubation strategies were applied
in our study: (1) Measurement of VLCFA-sensitive parameters after
acute exposure to supraphysiological concentrations of VLCFA.
(2) 24 h-pretreatment of astrocytes with relatively low concentrations
of VLCFA, followed by the acute exposure to a higher concentration of
VLCFA. The second strategy may have the advantage that pretreated
cells become sensitized to deleterious activities of VLCFA. We are
aware that this strategy only poorly mimics the situation of the interac-
tion of neural cells with VLCFA in patients suffering from X-ALD. In ad-
dition, mitochondria from one-year-old Abcd1−/−micewere examined
for their response to ADP or ADP plus C22:0 (Table 1). State 3 respira-
tion, i.e. oxidative phosphorylation was not affected.4.2. Structure-dependent VLCFA-toxicity is different for astrocytes and
mitochondria
When applying the VLCFA C22:0, C24:0 and C26:0 to astrocytes or to
isolated brainmitochondria, therewas a surprising observationwith re-
gard to the hydrocarbon chain length of VLCFA. Thus, C26:0 exerts sim-
ilar or even higher detrimental activity on astrocytes like C22:0 or C24:0
does (Figs. 1, 3, and 10), whereas C26:0 was nearly without any effect
on mitochondria (Figs. 4, 5 and 6). It can be speculated that the pro-
nounced detrimental activity of C22:0 on mitochondria results from
its easier escape from the cyclodextrin vesicles to mitochondria com-
bined with a higher ﬂip-ﬂop mobility in the IMM. The latter property
would explain the higher protonophoric activity of C22:0 on the IMM
of mitochondria (Figs. 4C and 5A).
It is generally accepted that mitochondria and peroxisomes are im-
portant sites of the ROS generation in cells (for review see [63]). There-
fore, a further question arises: Do astrocytes from Abcd1−/− and from
wild-type mice differ with respect to the ROS generation, particularly
when they are exposed to pathophysiological concentrations of
VLCFA? Here, we show that the intracellular ROS generation in untreat-
ed astrocytes from wild-type and Abcd1−/−mice are not different from
each other and, in addition, they are similarly stimulated by acute expo-
sure to VLCFA (Fig. 1). Nevertheless, the highest induction of the ROS
generation was found in astrocytes of Abcd1−/− mice during short-
time exposure with C26:0. Surprisingly, when Abcd1−/− astrocytes,
pretreated with a lower concentration of VLCFA for 24 h, were exposed
thereafter to a higher concentration of VLCFA, their ROS generation was
similarly increased by C22:0, C24:0 or C26:0. This ﬁnding might be ex-
plained in the light of VLCFA-associated decreased regeneration of oxi-
dized pyridine nucleotides (Fig. 9) as follows: It seems likely that
pretreated Abcd1−/− astrocytes exhibit a diminished NAD(P)H-depen-
dent regeneration capacity of oxidized glutathione. Consequently ROS
production becomes to a lesser extent inactivated by the cellular gluta-
thione peroxidase.
This conclusion could also explain that oxidative stress is obviously
higher in Abcd1−/− astrocytes, as indicated by stronger lipid peroxida-
tion (Fig. 2). Similar to the in situ Δψm measurements, the effect of
VLCFA in Abcd1−/− astrocytes was dramatically potentiated when
cells were treated with these fatty acids over a longer time period, indi-
cated by enhanced reduction of Δψm in mitochondria of Abcd1−/− as-
trocytes compared to cells from wild-type mice (Fig. 3).
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generation
An impairment of the electron ﬂow in the respiratory chain by
free fatty acids enhanced the ROS generation in the forward mode
(FET), whereas the depolarization of IMM by fatty acid-associated
mild uncoupling decreased ROS formation in the reverse mode
(RET) [64]. Therefore, possible effects of VLCFA on the IMM were
studied with isolated brain mitochondria from wild-type and
Abcd1−/− mice. In both types of mitochondria, the response to
VLCFA was remarkably similar for i) increase of the FET-driven ROS
production (Fig. 4B) and for ii) decrease of the RET-driven ROS gen-
eration (Fig. 4C). These responses were most prominent with C22:0.
In contrast, a severe Δψm decrease in wild-type astrocytes occurred
after acute exposure to VLCFA, where for C26:0 a surprising observa-
tion was made, since C26:0 has no signiﬁcant detrimental activity on
isolated mitochondria (Figs. 4 and 5). Moreover, in contrast to the
ROS measurements in astrocytes, where C22:0, C24:0 and C26:0
exert, after long-time exposure, a similarly strong effect on ROS pro-
duction, an acute exposure of brain mitochondria to C22:0 has the
largest effect. Therefore, it is conceivable that besides the peroxi-
somes, VLCFA also activate further non-mitochondrial sources of
ROS generation in astrocytes. Finally, we have to consider the follow-
ing: since in the in vivo situation brain mitochondria are predomi-
nantly supplied by NADH-donating substrates, the effects of VLCFA
on the FET-dependent ROS generation are of much higher relative
physiological relevance than the inﬂuence on RET.
We could verify that especially C22:0 directly inﬂuences the IMM, as
shownby the increase of the resting respiration and impairment of state
3 respiration (Fig. 5). The ﬁrst activity results frommild uncoupling, and
the second activity is due to impaired electron transport and inhibition
of the combined activity of FOF1-ATP synthase plus adenine nucleotide
translocase. Interference of fatty acids with the mitochondrial electron
transport has been well documented [50,65,66] and is best explained
by a destabilization of the membrane through incorporation of VLCFA
and, possibly, by dissociation of cytochrome c from the IMM [67–69].4.4. Energy-dependent parameters are not different for brain mitochondria
isolated from wild-type and Abcd1−/− animals
Notable is our ﬁnding that the energy-dependent parameters (Δψm,
ADP-dependent respiration and ROS generation) in untreated brainmi-
tochondria either measured in situ or in vitro do not differ for wild-type
and Abcd1−/− mice. This suggests that the loss of the ABCD1-protein
fromperoxisomes has nodirect effect on these functionalmitochondrial
parameters [45]. This is in line with our observation that Δψm and ROS
production are comparable in untreated astrocytes (Figs. 1, 3, 4, and
5), whereas the long-term treatment of cells with VLCFA resulted in a
signiﬁcantly stronger impairment in Abcd1 knockout.
We have to come back to the increased ROS generation in VLCFA-
treated astrocytes (Fig. 1), especially in Abcd1−/− astrocytes after expo-
sure to C26:0,which is highly increased in X-ALDpatients. This indicates
an increased vulnerability of Abcd1−/− cells to C26:0 and a crucial role
of C26:0 in the pathogenesis of X-ALD. Furthermore,when Abcd1−/− as-
trocyteswere treatedwithVLCFA for a longer period of time the amount
of ROS production more dramatically increased in these cells than in
VLCFA-treated wild-type astrocytes in which the ROS formation
remained almost the same as in acutely stimulated wild-type cells. A
comparable effect of enhanced ROS production was shown for Abcd1-
silenced 158 N oligodendrocytes, in which VLCFA incubation leads to a
stronger formation of superoxide anions and hydrogen peroxide as
compared to non-silenced cells [26]. These results indicate a link be-
tween oxidative stress and ABCD1 deﬁciency that may also be the
cause of the increased level of lipid peroxidation detected in Abcd1−/−
astrocytes (Fig. 2).4.5. Alteration of the intracellular Ca2+ handling by VLCFA
An important target of VLCFA is the intracellular Ca2+ homeostasis.
In neural cells of rat brain hippocampus, VLCFA evoke irregular asyn-
chronous Ca2+ oscillations similar to a glutamate-induced Ca2+ re-
sponse [39]. When we investigated the intracellular Ca2+ response
due to VLCFA application in Abcd1−/− and wild-type astrocytes, we
found a synchronous immediate Ca2+ reaction of all cells. Importantly,
we detected a signiﬁcantly lower VLCFA-induced increase in the intra-
cellular Ca2+ level in Abcd1−/− astrocytes than in wild-type cells.
Long-term treatment of astrocytes with VLCFA potentiated the cellular
effect of the fatty acids (Fig. 7). The intracellular Ca2+ level in wild-
type and Abcd1−/− cells increased dramatically. The observed effect of
a weaker intracellular Ca2+ increase in Abcd1−/− astrocytes after
acute exposure to VLCFA was almost abolished in cells which were
pre-treated with the VLCFA. The latter could be attributed to the ability
of saturated, long-chain fatty acids to up-regulate the expression of
Ca2+-binding proteins in the central nervous system [70].
To exclude a disturbed Ca2+ load of intracellular Ca2+ stores, we in-
vestigated store depletion by CPA and subsequent Ca2+ inﬂux. Our re-
sults show that the difference in VLCFA-mediated Ca2+ increase does
not rely on amalfunctioning of intracellular Ca2+ stores in Abcd1−/− as-
trocytes. This ﬁnding shifts our attention to a disturbed Ca2+ signaling
in Abcd1−/− cells, either due to altered functions of a membrane recep-
tor or defects in the signaling cascade or the release of intracellular
Ca2+.
4.6. VLCFA promote the cell death in astrocytes
Moreover, mitochondrial Ca2+ accumulation can trigger the distur-
bance of the Δψm, which further favors the opening of the PTP [71].
Thus, we studied PTP opening by estimating the CRC, which was
found to be slightly higher in mitochondria from Abcd1−/− mice
(Fig. 6). This could be related to the decreased Ca2+ rise in Abcd1−/− as-
trocytes after acute VLCFA application. It is conceivable that due to the
higher CRC of mitochondria from Abcd1−/− mice a higher amount of
the intracellular Ca2+ release was buffered by these mitochondria,
resulting in a weaker Ca2+ response in Abcd1−/− cells. Moreover, we
found that the reduction of the Δψm due to VLCFA exposure, especially
with C22:0, lowered the CRC and sensitized for opening of PTP. This is
in agreement with recent reports indicating an increased sensitivity of
X-ALD patient's ﬁbroblasts to opening of PTP and consequent cell
death, involving oxidation of the pore components cyclophilin D and
ATP synthase [25].
Indeed, oxidative stress as well as intracellular Ca2+ overload are
PTP opening trigger events initiating cell death and are therefore impor-
tant mediators of toxicity [72]. The property of VLCFA to induce the
death of Abcd1−/− astrocytes increasedwith the length of the hydrocar-
bon chain of VLCFA. A similar relation between the cytotoxicity of fatty
acids and their chain length has been already reported for polyunsatu-
rated fatty acids [73,74]. Thus, again, C26:0, which has the lowest detri-
mental activity on mitochondria (Figs. 4C, 5 and Fig. 6), exerts the
highest cell toxicity (see also [39]). This ﬁnding indicates that the
VLCFA-induced astrocytic cell death is not exclusively due to a detri-
mental effect of VLCFA on mitochondria.
4.7. Conclusion on toxicity of VLCFA and therapeutic outlook
In summary, astrocytes from Abcd1−/−mouse respond more sensi-
tively to VLCFA, mainly indicated by the cellular ROS generation
(Fig. 1), in situ depolarization of mitochondria (Fig. 3) and reduced re-
duction of tetrazolium (Fig. 9). The latter feature, the VLCFA-induced
decrease of tetrazolium reduction by Abcd1−/− astrocytes, is of special
signiﬁcance. This property was reported here for the ﬁrst time. This
ﬁnding suggests that in contrast towild-type astrocytes, VLCFA dramat-
ically diminish the regeneration of NAD(P)H in Abcd1−/− astrocytes.
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derivatives is taken prima vista as a measure of cell proliferation/
survival. But our ﬁnding is suggestive for the hypothesis that an im-
paired regeneration of NAD(P)H contributes to the shortening of the
life-expectancy of Abcd1−/− astrocytes, because most likely the
glutathione-dependent inactivation of lipid hydrogen peroxides andhy-
drogen peroxide are affected. Consequently, VLCFA-exposed Abcd1−/−
astrocytes suffer more under oxidative stress than wild-type astrocytes.
Future work is required for further enlightening of this concept.
In addition, a disturbed Ca2+ signaling seems to be involved in the
pathogenesis of X-ALD. Thus, Abcd1−/− astrocytes displayed a much
lower intracellular Ca2+ reaction in response to acute VLCFA application
(Fig. 7). In contrast we observed lack in difference in mitochondrial re-
spiratory functions in control MBM and in Abcd1−/−MBM. Ca2+, which
plays a key role in neural signaling in the brain, is of paramount impor-
tance for the control of neurodegenerative diseases, like Alzheimer's
disease, Parkinson's disease, and Huntington's disease [75]. Thus, the
weaker Ca2+ response to VLCFA inAbcd1−/− astrocytes highlights a fur-
ther physiological parameter and indicates a therapeutic target for X-
ALD.
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